國立臺灣大學-技術交易網

去整合蛋白變異體及其醫藥用途(DISINTEGRIN VARIANTS AND PHARMACEUTICAL USES THEREOF)

刊登日期：2014/05/21

‧ 專利名稱	去整合蛋白變異體及其醫藥用途(DISINTEGRIN VARIANTS AND PHARMACEUTICAL USES THEREOF)
‧ 專利證書號	- CN101677537B JP05908666B2 HK1136160B SG201400709B EP2124548B1 AU2007343734B2
‧ 專利權人	台大(50％)、成大(50％)
‧ 專利國家 (申請日)	紐西蘭 () PCT (2007/12/21) 中國 (2007/12/21) 歐洲 (2007/12/21) 巴西 (2009/06/25) 日本 (2009/06/25) 以色列 (2009/06/25) 墨西哥 (2009/06/26) 澳洲 (2009/06/26) 印度 (2009/07/07) 俄羅斯 (2009/07/24) 韓國 (2009/07/24) 香港 (2010/03/30) 新加坡 (2012/08/03)

‧ 發明人/PI	莊偉哲,符文美,黃德富,黃溫雅,湯智昕,陳秋月,
‧ 單位	藥理學科暨研究所
‧ 簡歷/Experience

技術摘要 / Our Technology：

Disintegrin variants and pharmaceutical uses thereof are disclosed. The disintegrin variant includes an isolated polypeptide that has integrin αvβ3 receptor-antagonist activity and substantially reduced integrin αllbβ3 and/or α5β1 receptor-blocking activity as compared to a wild-type disintegrin. The variant is encoded by a modified disintegrin nucleotide sequence that encodes a modified amino acid sequence, resulting in a polypeptide having substantially reduced affinity to integrin αllbβ3 and/or α5β1 as compared to a wild-type disintegrin. The variant is useful for treatment and/or prevention of αvβ3 integrin-associated diseases in a mammal, which include osteoporosis, bone tumor or cancer growth, angiogenesis-related tumor growth and metastasis, tumor metastasis in bone, malignancy-induced hypercalcemia, angiogenesis-related eye diseases, Paget's disease, rheumatic arthritis, and osteoarthritis. The angiogenesis-related eye diseases include age-related macular degeneration, diabetic retinopathy, corneal neovascularizing diseases, ischaemia-induced neovascularizing retinopathy, high myopia, and retinopathy of prematurity.

聯繫方式 / Contact：

臺大產學合作總中心 / Center of Industry-Academia Collaboration, NTU

Email：ordiac@ntu.edu.tw	電話/Tel：02-3366-9945

可授權技術分類